| 2020-BAO-68927 | |
| Researchers at Purdue University have developed a new means to efficiently generate hematopoietic stem cells for use in blood diseases, cancer therapy and regenerative medicine. Humans generate specific red and white blood cell types from a common precursor, the hematopoietic stem cell (HSC). HSC transplantation is an important therapeutic option for many blood diseases, cancers and immunodeficiencies, replacing diseased blood cell populations. However, HSCs are currently in short supply as they are typically extracted from humans. The Purdue University researchers have responded to this need by developing a serum-free, in vitro directed differentiation protocol to generate human HSCs from pluripotent stem cells. These HSCs have been proven capable of generating white and red blood cell progeny. In further validation of this technology, the HSCs implanted into zebrafish embryos colonized the hematopotietic tissues of the growing chimeric fish. Altogether, this technology provides a needed step towards production of HSCs to treat patients suffering from blood diseases, cancer and immunodeficient conditions. Advantages: -Increased HSC production -No human blood or serum needed -Cost-effective and reproducible Potential Applications -Biomanufacturing -Cell Therapy -Cancer Treatment -Regenerative Medicine |
|
|
|
|
Feb 22, 2021
PCT-Patent
WO
(None)
(None)
Feb 28, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |